

# Nada Lallous

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6542393/publications.pdf>

Version: 2024-02-01

35  
papers

940  
citations

516215

16  
h-index

454577

30  
g-index

38  
all docs

38  
docs citations

38  
times ranked

1617  
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. <i>Genome Biology</i> , 2016, 17, 10.	3.8	165
2	Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201). <i>European Urology</i> , 2018, 73, 4-8.	0.9	75
3	Structure, Functional Characterization, and Evolution of the Dihydroorotase Domain of Human CAD. <i>Structure</i> , 2014, 22, 185-198.	1.6	60
4	Identification of a Potent Antiandrogen that Targets the BF3 Site of the Androgen Receptor and Inhibits Enzalutamide-Resistant Prostate Cancer. <i>Chemistry and Biology</i> , 2014, 21, 1476-1485.	6.2	59
5	Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 12496-12519.	1.8	51
6	Androgen receptor-binding sites are highly mutated in prostate cancer. <i>Nature Communications</i> , 2020, 11, 832.	5.8	44
7	Androgen receptor plasticity and its implications for prostate cancer therapy. <i>Cancer Treatment Reviews</i> , 2019, 81, 101871.	3.4	40
8	An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer. <i>European Urology</i> , 2017, 72, 142-150.	0.9	38
9	Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. <i>European Journal of Medicinal Chemistry</i> , 2018, 160, 108-119.	2.6	38
10	The PHD Finger of Human UHRF1 Reveals a New Subgroup of Unmethylated Histone H3 Tail Readers. <i>PLoS ONE</i> , 2011, 6, e27599.	1.1	36
11	Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models. <i>Journal of Clinical Investigation</i> , 2019, 130, 699-714.	3.9	36
12	Computer-Aided Discovery of Small Molecules Targeting the RNA Splicing Activity of hnRNP A1 in Castration-Resistant Prostate Cancer. <i>Molecules</i> , 2019, 24, 763.	1.7	29
13	Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2936-2945.	1.9	24
14	Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2281-2291.	1.9	22
15	In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor $\beta$ . <i>Breast Cancer Research</i> , 2015, 17, 27.	2.2	20
16	Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics. <i>Frontiers in Oncology</i> , 2020, 10, 633142.	1.3	19
17	Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2493.	1.8	17
18	Cheminformatics Modeling of Adverse Drug Responses by Clinically Relevant Mutants of Human Androgen Receptor. <i>Journal of Chemical Information and Modeling</i> , 2016, 56, 2507-2516.	2.5	16

#	ARTICLE	IF	CITATIONS
19	Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 3488.	1.7	16
20	Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8277.	1.8	14
21	Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5847.	1.8	14
22	Expression, purification, crystallization and preliminary X-ray diffraction analysis of the dihydroorotase domain of human CAD. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2012, 68, 1341-1345.	0.7	12
23	Expression, purification, crystallization and preliminary X-ray diffraction analysis of the aspartate transcarbamoylase domain of human CAD. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2013, 69, 1425-1430.	0.7	12
24	Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients. <i>Cancers</i> , 2021, 13, 2939.	1.7	12
25	20(S)-protopanaxadiol regio-selectively targets androgen receptor: anticancer effects in castration-resistant prostate tumors. <i>Oncotarget</i> , 2018, 9, 20965-20978.	0.8	12
26	Expression, purification, crystallization and preliminary crystallographic study of the SRA domain of the human UHRF1 protein. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2008, 64, 922-925.	0.7	9
27	Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor- $\alpha$ in Hormone-Resistant Breast Cancers. <i>International Journal of Molecular Sciences</i> , 2018, 19, 579.	1.8	9
28	Development of 2-(5,6,7-Trifluoro-1H-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14968-14982.	2.9	9
29	Optimization of New Catalytic Topoisomerase II Inhibitors as an Anti-Cancer Therapy. <i>Cancers</i> , 2021, 13, 3675.	1.7	8
30	Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2588.	1.8	7
31	Drug-Discovery Pipeline for Novel Inhibitors of the Androgen Receptor. <i>Methods in Molecular Biology</i> , 2016, 1443, 31-54.	0.4	4
32	Head-to-head comparison of efficacy of darolutamide (ODM-201) vs. enzalutamide on mutated forms of the androgen receptor. <i>European Urology Supplements</i> , 2018, 17, e505.	0.1	1
33	Abstract 3653: Structure-based study to overcome cross-reactivity of novel androgen receptor inhibitors. , 2015, , .		0
34	Abstract 4644: Inhibition of the androgen receptor at two drug-targetable sites on the DNA-binding domain protein surface. , 2016, , .		0
35	Targeting HP1-alpha for prevention and treatment of neuroendocrine prostate cancer. <i>Oncology Abstracts</i> , 0, , .	0.0	0